Barrett's esophagus secondary prevention: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Barrett's esophagus}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References== {{...") |
Hamid Qazi (talk | contribs) No edit summary |
||
| (9 intermediate revisions by 5 users not shown) | |||
| Line 2: | Line 2: | ||
{{Barrett's esophagus}} | {{Barrett's esophagus}} | ||
{{CMG}}; {{AE}}; {{HQ}}, {{AMK}} | |||
==Overview== | |||
Effective measures for the secondary prevention of Barrett's esophagus include primary prevention along with endoscopic surveillance every 3-5 years for no [[dysplasia]], 6-12 months for low-grade [[dysplasia]], and every 3 months for high-grade [[dysplasia]] in the [[absence]] of [[eradication]] [[therapy]]. | |||
==Secondary prevention== | |||
Recommendations for secondary prevention of Barrett's esophagus include the primary prevention along with the following: | |||
*[[Barrett's esophagus]] is a major [[risk factor]] for [[development]] of [[esophageal]] [[adenocarcinoma]]. | |||
*After [[diagnosis]], regular surveillance is needed based on the grade of [[dysplasia]]. | |||
*[[Strong]] [[recommendation]], low-quality [[evidence]] [[against]] [[screening]] [[general]] [[population]] [[with]] [[GERD]] and no [[risk factors]].<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011 |month=March |}}</ref> | |||
[[Weak]] [[recommendation]], moderate-quality [[evidence]]: [[Endoscopic]] [[surveillance]] in [[patients]] [[with]] [[Barrett's esophagus]] | |||
The [[following]] [[intervals]] are [[recommended]]: | |||
* No [[dysplasia]]: 3–5 [[years]]. | |||
* Low-grade [[dysplasia]]: 6–12 [[months]]. | |||
* High-grade [[dysplasia]] in the [[absence]] of [[eradication]] [[therapy]]: 3 months.<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011 |month=March |pmid=21376940 |doi=10.1053/j.gastro.2011.01.030 |url=}}</ref> | |||
* [[Therapy]] with [[medications]] effective to treat [[GERD]] [[symptoms]] and to heal [[reflux esophagitis]] is strongly recommended. | |||
* Do not attempt to eliminate [[acid]] exposure of the [[esophagus]] | |||
# Use [[proton pump inhibitors]] in [[doses]] greater than once daily. There is no [[evidence]] that higher [[doses]] produce a risk [[reduction]] in [[cancer]]. | |||
# [[Titrate]] [[proton pump inhibitors]] [[dose]] by [[esophageal]] [[pH]] monitoring. | |||
# Anti-reflux [[surgery]]. This is not more effective than [[medical]] therpay. | |||
[[Risks]] and benefits of long-term [[PPI]] [[therapy]] should be discussed with the [[patients]]. | |||
* Do not use [[aspirin]] to prevent [[esophageal]] [[adenocarcinoma]] in the absence of other indications (e.g. [[cardiovascular]] [[risk factors]]). Although [[evidence]] suggests [[NSAIDs]] may decrease the [[incidence]] of [[esophageal]] [[cancer]], it is not clear if benefits outweight the [[risks]] of using this [[medications]].<ref name="pmid21376940">{{cite journal |author=Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ |title=American Gastroenterological Association medical position statement on the management of Barrett's esophagus |journal=Gastroenterology |volume=140 |issue=3 |pages=1084–91 |year=2011 |pmid=21376940 |doi=10.1053/j.gastro.2011.01.030 |url=}}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category: (name of the system)]] | |||
Latest revision as of 16:28, 5 February 2018
|
Barrett's Esophagus Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Barrett's esophagus secondary prevention On the Web |
|
American Roentgen Ray Society Images of Barrett's esophagus secondary prevention |
|
Risk calculators and risk factors for Barrett's esophagus secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: ; Hamid Qazi, MD, BSc [2], Amresh Kumar MD [3]
Overview
Effective measures for the secondary prevention of Barrett's esophagus include primary prevention along with endoscopic surveillance every 3-5 years for no dysplasia, 6-12 months for low-grade dysplasia, and every 3 months for high-grade dysplasia in the absence of eradication therapy.
Secondary prevention
Recommendations for secondary prevention of Barrett's esophagus include the primary prevention along with the following:
- Barrett's esophagus is a major risk factor for development of esophageal adenocarcinoma.
- After diagnosis, regular surveillance is needed based on the grade of dysplasia.
- Strong recommendation, low-quality evidence against screening general population with GERD and no risk factors.[1]
Weak recommendation, moderate-quality evidence: Endoscopic surveillance in patients with Barrett's esophagus The following intervals are recommended:
- High-grade dysplasia in the absence of eradication therapy: 3 months.[1]
- Therapy with medications effective to treat GERD symptoms and to heal reflux esophagitis is strongly recommended.
- Use proton pump inhibitors in doses greater than once daily. There is no evidence that higher doses produce a risk reduction in cancer.
- Titrate proton pump inhibitors dose by esophageal pH monitoring.
- Anti-reflux surgery. This is not more effective than medical therpay.
Risks and benefits of long-term PPI therapy should be discussed with the patients.
- Do not use aspirin to prevent esophageal adenocarcinoma in the absence of other indications (e.g. cardiovascular risk factors). Although evidence suggests NSAIDs may decrease the incidence of esophageal cancer, it is not clear if benefits outweight the risks of using this medications.[1]